Clinical Trials Logo

Filter by:
NCT ID: NCT06212882 Recruiting - Pulmonary Embolism Clinical Trials

Optimization of DE-CTPA Images and Diagnostic Pathway: Using Low Concentration Iodine Contrast Material

Start date: September 1, 2023
Phase:
Study type: Observational

The investigators aimed to compare the image quality and diagnostic performance of DECTPA using lower concentration iodine contrast materials and using normal concentration iodine contrast materials in the evaluation of suspected pulmonary embolism.

NCT ID: NCT06212297 Recruiting - Clinical trials for Inherited Retinal Dystrophy

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Start date: September 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.

NCT ID: NCT06212154 Recruiting - Clinical trials for Autoimmune Hemolytic Anemia

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Start date: January 20, 2024
Phase: Phase 1
Study type: Interventional

To Evaluate the Safety and Efficacy of ThisCART19A for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy

NCT ID: NCT06211881 Recruiting - Clinical trials for Relapsed/Refractory Peripheral T-cell Lymphoma

Chi-GVM Regimen for the Treatment of R/R PTCL

Start date: October 25, 2023
Phase: N/A
Study type: Interventional

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoproliferative diseases caused by mature T cells, accounting for approximately 10% of non-Hodgkin lymphomas (NHL). PTCLs have a worse prognosis than aggressive B-cell lymphomas; they are less responsive to standard anthracycline-based chemotherapy regimens and responses are less durable. In an analysis of 341 patients with newly diagnosed PTCL who received anthracycline chemotherapy, 3-year PFS and OS rates were 32% and 52%, respectively, significantly inferior to matched patients with diffuse large B-cell lymphoma (DLBCL).And patients who received consolidative hematopoietic cell transplantation (HCT) had no significant benefit. The prognosis of relapsed/refractory (R/R) patients is even worse. Among the 420 evaluable R/R PTCL patients in the COMPLETE registration study, the median OS of R/R patients were 29 months and 12 months respectively . There is still no effective second-line regimen that can improve patient survival, so treatment options urgently need to be optimized.We designed a randomized, prospective, multi-center phase II clinical trial to explore the efficacy of chidamide combined with gemcitabine, vinorelbine and Mitoxantrone Hydrochloride Liposome (Chi-GVM) in the treatment of patients with R/R PTCL. We expected to further improve ORR, PFS and OS.

NCT ID: NCT06211790 Recruiting - Clinical trials for Renal Cell Carcinoma

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Start date: January 16, 2024
Phase: Phase 2
Study type: Interventional

Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.

NCT ID: NCT06211764 Recruiting - Clinical trials for Non-Muscle Invasive Bladder Neoplasms

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

SunRISe-5
Start date: April 9, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.

NCT ID: NCT06211647 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-XT117 injection in patients with FAP-positive advanced solid tumors. Dose escalation will be conducted to determine the Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D), and to assess dosimetry characteristics.

NCT ID: NCT06211439 Recruiting - Clinical trials for Consciousness Disorders

Transcranial Alternating Current Stimulation in Patients With Disorders of Consciousness

Start date: December 5, 2022
Phase: N/A
Study type: Interventional

In recent years, many literatures have reported that tACS, as a non-invasive electrical brain stimulation technique, has been applied in depression, schizophrenia, dementia and other fields. The goal of this study is to explore the clinical efficacy and mechanism of action of HD-tACS in patients with chronic disorders of consciousness.The main questions it aims to answer are: 1. Explore the neurophysiological effects of HD-tACS on patients with chronic disorders of consciousness under theta and gamma frequency stimulation, and observe its impact on behavioral changes and long-term prognosis; 2. Further investigate the awakening mechanism of consciousness disorders through HD-tACS stimulation using multimodal assessment; 3. Clarify the role of theta and gamma neural oscillations in consciousness disorders, providing new targets for the pathogenesis and treatment of Disorders of Consciousness .

NCT ID: NCT06211218 Recruiting - Clinical trials for Deep Learning, Corneal Disease, Screening

Artificial Intelligence for Screening of Multiple Corneal Diseases

Start date: December 6, 2020
Phase:
Study type: Observational

This study developed a deep learning algorithm based on anterior segment images and prospectively validated its ability to identify corneal diseases.The effectiveness and accuracy of this algorithm was evaluated by sensitivity, specificity, positive predictive value, negative predictive value, and area under curve.

NCT ID: NCT06211166 Recruiting - Acute Leukemia Clinical Trials

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Start date: January 8, 2024
Phase:
Study type: Observational

A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.